)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Basilea Pharmaceutica (BSLN) investor relations material
Basilea Pharmaceutica H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary19 Aug, 2025
Executive summary
Achieved 36.3% year-over-year revenue growth to CHF104M in H1 2025, with a 24.8% increase in Cresemba global in-market sales and 21.7% higher royalty income.
Launched Zevtera in the US, expanding commercial reach and addressing high unmet medical needs in severe infections.
Advanced pipeline with a second Phase III study for fosmanogepix and in-licensed ceftibuten-ledobarbactam, a Phase III-ready oral antibiotic for complicated UTIs.
Secured $39M in non-dilutive BARDA funding to support antifungal R&D.
Strengthened financial position through debt reduction, including CHF14.3M in convertible bond repurchases, and positive operating cash flow.
Financial highlights
Total revenue reached CHF104M in H1 2025, up 36% year-on-year, with Cresemba & Zevtera revenue at CHF90.5M (+23.5%).
Operating profit surged to CHF24M, a 160% increase year-on-year.
Net profit was CHF15.8M, down from CHF20.7M in 2024 due to a one-time tax benefit last year.
Net cash position improved to CHF50.7M as of June 30, 2025, from net debt of CHF-26.2M a year earlier.
Operating cash flow was CHF23.1M, up from CHF17.9M in 2024.
Outlook and guidance
FY 2025 revenue guidance updated to above CHF220M–225M, with Cresemba and Zevtera revenue projected at CHF190M and royalty income expected to grow 14% to CHF110M.
Operating profit for 2025 expected at approximately CHF50M, reflecting increased R&D investment.
R&D expenses projected to rise to CHF105M, mainly due to in-licensing costs.
Anticipate a 17% reduction in product revenue due to decreased supply to Pfizer, offset by royalty growth.
Focus on advancing antifungal pipeline, new asset scouting, and maintaining leadership in anti-infectives.
Assess fosmanogepix expanded access data utility.
Explain ceftibuten-ledaborbactam Phase III timeline.
Innoviva's Zevtera sales infrastructure details?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Basilea Pharmaceutica earnings date
H2 202517 Feb, 2026
Next Basilea Pharmaceutica earnings date
H2 202517 Feb, 2026
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Basilea Pharmaceutica AG is a biopharmaceutical company specializing in the research, development, and commercialization of hospital anti-infectives and oncology medicines. It focuses on therapies addressing antimicrobial resistance and cancer. The company is headquartered in Basel, Switzerland, and its shares are listed on the SIX Swiss Exchange.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage